{"id":"NCT04652726","sponsor":"Novartis Pharmaceuticals","briefTitle":"Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia","officialTitle":"Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Inclisiran in Adolescents (12 to Less Than 18 Years) With Heterozygous Familial Hypercholesterolemia and Elevated LDL-cholesterol (ORION-16)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-01-27","primaryCompletion":"2023-11-09","completion":"2024-11-27","firstPosted":"2020-12-03","resultsPosted":"2025-06-10","lastUpdate":"2025-06-10"},"enrollment":141,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Familial Hypercholesterolemia - Heterozygous"],"interventions":[{"type":"DRUG","name":"Inclisiran","otherNames":["KJX839"]},{"type":"DRUG","name":"Placebo","otherNames":["Saline solution"]}],"arms":[{"label":"Inclisiran","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This was a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in adolescents with heterozygous familial hypercholesterolemia (HeFH) and elevated low density lipoprotein cholesterol (LDL-C).","primaryOutcome":{"measure":"Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1)","timeFrame":"Baseline and Day 330","effectByArm":[{"arm":"Part 1- Inclisiran","deltaMin":-27.14,"sd":null},{"arm":"Part 1 - Placebo","deltaMin":1.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<.0001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":59,"countries":["United States","Argentina","Brazil","Canada","Czechia","France","Germany","Greece","Hungary","Israel","Italy","Jordan","Lebanon","Malaysia","Netherlands","Norway","Poland","Russia","Slovakia","Slovenia","South Africa","Spain","Switzerland","Taiwan","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["35175352","33990512"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":93},"commonTop":["COVID-19","Nasopharyngitis","Influenza","Headache","Injection site reaction"]}}